POLYMEDIC, INC. (OTCBB: PYMX) $85M (MARKETCAP) SUCCESSFULLY COMPLETES PHASE 1B CLINICAL STUDY
PolyMedic, Inc. (OTCBB: PYMX) M (MarketCap) Successfully Completes Phase 1B Clinical Study
Free Online Articles Directory
Why Submit Articles?
Top Authors
Top Articles
FAQ
AB Answers
0 && $.browser.msie ) {
var ie_version = parseInt($.browser.version);
if(ie_version Hello Guest
Login
Register
Hello
My Home
Sign Out
Email
Password
Remember me?
Lost Password?
Home Page > Finance > PolyMedic, Inc. (OTCBB: PYMX) M (MarketCap) Successfully Completes Phase 1B Clinical Study
PolyMedic, Inc. (OTCBB: PYMX) M (MarketCap) Successfully Completes Phase 1B Clinical Study
Posted: June 03, 2010 |Comments: 0
|
]]>
PolyMedic, Inc. (OTCBB: PYMX) M (MarketCap) Successfully Completes Phase 1B Clinical Study
About the Author
About World Market Media:
WorldMarketMedia.com (The Global Online Investment Community) is the tall trade batch market, headlines interpretation website upon condition which slicing corner brand brand brand new media products as good as services to publicly traded companies worldwide. Our Editor’s Desk authors judicious real-time coverage upon the economy, the collateral markets as good as their listed companies.
(ArticlesBase SC #2534646)
Article Source: http://www.articlesbase.com/ – PolyMedic, Inc. (OTCBB: PYMX) M (MarketCap) Successfully Completes Phase 1B Clinical Study
PolyMedix, Inc. (OTCBB: PYMX) is an rising biotechnology association focused upon building brand brand brand new healing drug to provide strident cardiovascular disorders as good as spreading diseases. Today, it voiced the successful execution of the second Phase 1B clinical reserve as good as commander efficiency investigate with PMX-60056, the tiny fake proton written to retreat the anticoagulant wake up of both Heparin as good as Low Molecular Weight Heparin (LMWH). The interpretation from this investigate uncover which PMX-60056 met the investigate reserve as good as efficiency endpoints per the annulment of the anticoagulant wake up of the LMWH tinzaparin.
Low Molecular Weight Heparins have been used in we estimate twelve million patients annually for ongoing diagnosis of thrombosis. Up to 20% of patients might knowledge draining complications. With no stream FDA authorized product accessible to retreat the anticoagulant wake up of LMWHs, most of these patients might need life-saving operation or red red blood transfusions to provide their draining complications. Herapin is an i.v. anticoagulant used to forestall clots from combining during sure cardiothoracic as good as orthopedic surgical procedures. After these procedures, the anticoagulant wake up of heparin contingency be topsy-turvy in sequence to revive normal clot formation. There is the vital need for pick heparin reversing agents which have been safer as good as simpler to use, due to the existent Promatine which has most limitations. PMX-60056 pre-clinical as good as clinical interpretation indicate most intensity reserve as good as alternative advantages over promatine, as good as the potentially singular event to be the initial reversing representative for LMWHs.
Highlights from the Phase 1B clinical investigate include:
PMX-60056 neutralized the anticoagulant wake up of LMWH tinzaparin
PMX-60056 normalized red red blood clotting time
PMX-60056 was safely administered in humans with no critical inauspicious events occurring in the study
With the diagnosis of we estimate twelve million patients annually, LMWH products have sum annual sales of over billion. This opens up the far-reaching window of profitability for PolyMedix with the successful execution of the PMX-60056 product.
“We hold draining complications compared with LMWHs paint the vital unmet healing need for the brand brand brand new reversing agent,” commented Nicholas Landekic, President & C.E.O. of PolyMedix. “There is no authorized reversing representative for LMWH. We hold which PMX-60056 is singular in being the initial as good as usually reversing representative in growth written to retreat the anticoagulant wake up of both unfractionated heparin as good as LMWH. This investigate has shown which PMX-60056 has the intensity to suggest critical benefits as good as improvements in treating these patients during risk of draining complications.”
Disclosure: no positions
To perspective this essay during World Market Media click upon the couple below: http://www.worldmarketmedia.com/779/section.aspx/1710/post/polymedic-inc-otcbb-pymx-85m-marketcap-successfully-completes-phase-1b-clinical-study
Retrieved from “http://www.articlesbase.com/finance-articles/polymedic-inc-otcbb-pymx-85m-marketcap-successfully-completes-phase-1b-clinical-study-2534646.html”
(ArticlesBase SC #2534646)
World Market Media -
About the Author:
About World Market Media:
WorldMarketMedia.com (The Global Online Investment Community) is the tall trade batch market, headlines data